Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LLY, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Tirzepatide FDA approved May 2022 · Mounjaro |
Type 2 Diabetes | Phase 4 · NCT05433584 | Active not recruiting |
| Dulaglutide FDA approved Sep 2014 · Trulicity |
Diabetes Mellitus, Type 2 | Phase 3 · NCT07668336 | Recruiting |
| Orforglipron FDA approved Apr 2026 · Foundayo |
Diabetes Mellitus, Type 2 | Phase 3 · NCT07668336 | Recruiting |
| Ramucirumab FDA approved Apr 2014 · Cyramza |
Gastric Cancer | Phase 2/3 · NCT05002127 | Completed |
| Abemaciclib FDA approved Sep 2017 · Verzenio |
Breast Neoplasms | Phase 2 · NCT07935317 | Not yet recruiting |
| Baricitinib FDA approved May 2018 · Olumiant |
HIV Infection | Phase 2 · NCT07209267 | Not yet recruiting |
| Imlunestrant FDA approved Sep 2025 · Inluriyo |
Healthy | Phase 1 · NCT07918859 | Not yet recruiting |
| Idelalisib | Chronic Lymphocytic Leukemia | Phase 4 · NCT07218341 | Recruiting |
| Antihyperglycemic medication | Type 2 Diabetes | Phase 4 · NCT05433584 | Active not recruiting |
| Pirtobrutinib | Chronic Lymphocytic Leukemia | Phase 4 · NCT07218341 | Recruiting |
| Evorpacept | Gastric Cancer | Phase 2/3 · NCT05002127 | Completed |
| Fluorouracil | Neoplasms | Phase 3 · NCT04607421 | Active not recruiting |
| LY3650150 | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 3 · NCT06338995 | Recruiting |
| Eloralintide | Obesity | Phase 3 · NCT07881432 | Not yet recruiting |
| Retatrutide | Obesity | Phase 3 · NCT07232719 | Active not recruiting |
| Irinotecan | Neoplasms | Phase 3 · NCT04607421 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not LLY's own candidates): Cetuximab, Encorafenib, Oxaliplatin, Paclitaxel, Capecitabine, Bevacizumab, Trastuzumab, Leucovorin, Obinutuzumab, Venetoclax, Anastrozole, Exemestane.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LLY holds $4.9B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LLY files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| LILLY ENDOWMENT INC Former 10% Shareholder |
Insider | 90,066,978 | 9.57% | 2026-09-30 |
| Blackrock Inc. | Institution (13F) | 67,936,153 | 7.22% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 61,295,605 | 6.52% | 2026-03-31 |
| PNC Financial Services Group, Inc. | Institution (13F) | 51,295,197 | 5.45% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 36,848,565 | 3.92% | 2026-09-30 |
| FMR, LLC | Institution (13F) | 29,959,147 | 3.18% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 20,999,744 | 2.23% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 20,556,572 | 2.19% | 2026-09-30 |
| Capital Research Global Investors | Institution (13F) | 16,998,595 | 1.81% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 16,377,649 | 1.74% | 2026-09-30 |
| Eli Lilly and Company | 5%+ holder (13D) | 6,344,114 | 0.67% | 2026-01-12 |
| LILLY & Co ELI 10% owner |
Insider | 1,104,558 | 0.12% | 2026-10-22 |
Share count 940,745,031 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-10 filed 2026-11-10 |
Jonsson Patrik |
Gift (G) | 704 | – | 53,443 |
| 2026-11-03 filed 2026-11-04 |
Ricks David A |
Gift (G) | 23,538 | – | 555,278 |
| 2026-11-02 filed 2026-11-03 |
Skovronsky Daniel |
Gift (G) | 119 | – | 159,953 |
| 2026-11-02 filed 2026-11-03 |
Hakim Anat |
Sale (S) | 5,000 | $1,402.52 | 4,137 |
| 2026-11-01 filed 2026-11-03 |
Custer Kenneth L. |
Option exercise (M) | 3,220 | – | 13,361 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LLY and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →